Skip to main navigation

About Us
- Our Core Values
- Our Team
Our Science
Clinical Research
- Pipeline
- RESOLVE
Patients
- Eosinophilic Esophagitis
- Expanded Access Program
Careers
Investors

Event Details

News & Events

News Releases
Events & Presentations

Virtual Analyst Day to Discuss EP-104GI for Eosinophilic Esophagitis

November 13, 2026 | 8:30 AM EST

Add to Outlook

Add to Google Calendar

Investor Contact

Kevin Gardner
Investor relations on behalf of Eupraxia Pharmaceuticals

draftskgardner@lifesciadvisors.com
draftsinvestors@eupraxiapharma.com

phone_iphone +617-283-2856

Subscribe to our Email Alerts

Email Address Required

Eupraxia is a clinical-stage biotechnology company developing targeted therapies that leverage a proprietary extended-release delivery system to provide the right dose of a drug in the right place for the right amount of time.

Vancouver lab & office:
Eupraxia Pharmaceuticals
2198 Yukon St,
Vancouver, BC, V5Y 3P1
Canada

Seattle office:
Eupraxia Pharma USA Inc.
5310 Carillon Point
Kirkland, WA 98033
USA

Get in Touch

Contact
Careers
250-590-3968

Follow us on :

Privacy Policy
Term of Use
IR Email Alerts

© 2026 Eupraxia Pharmaceuticals Inc. All rights reserved.

Search Investors

Search this site